Follow-on Offering

Healthcare
Follow-on Offering

Summary

Baird served as co-lead manager on this offering

About

Immunovant, Inc. (“Immunovant”) (NASDAQ-GS: IMVT) recently completed an underwritten public offering of 6,060,606 shares of its common stock at a public offering price of $33.00 per share, which included the exercise in full by the underwriters of their option to purchase an additional 790,513 shares of common stock. The aggregate gross proceeds to Immunovant from the offering are approximately $200.0 million.

Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies. Immunovant, Inc. is headquartered in New York, New York.
CONTACT US TO LEARN MORE
Healthcare
Follow-on Offering
Date
September 2020
Company
Immunovant, Inc.
Transaction
M&A
Sectors
Healthcare
Target Location
North America

Share